What Is the Difference Between Mounjaro and Zepbound? Eight Things That Actually Differ

Key Takeaways

• The active drug, tirzepatide, is identical in Mounjaro and Zepbound. The clinical effect on weight, blood sugar, and side effects is the same at the same dose.
• The eight real differences are FDA indication, NDC codes, eligibility criteria, prescribing information, insurance category, savings programs, dose-targeting strategy, and direct-to-consumer vial availability.
• Mounjaro was approved May 2022 for type 2 diabetes based on the SURPASS trials. Zepbound was approved November 2023 for chronic weight management based on SURMOUNT-1.
• The pen device, the molecule, the storage requirements, and the once-weekly injection schedule are identical between the two brands.
• For patients, the most consequential difference is insurance coverage, since most plans cover Mounjaro (diabetes) more readily than Zepbound (weight management).

Direct answer (40-60 words)

The difference between Mounjaro and Zepbound is administrative, not pharmacological. Both contain the same drug, tirzepatide, in identical pens at identical doses. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for chronic weight management. The diagnostic codes, insurance category, savings programs, and prescribing information differ, but the molecule and clinical effect do not.

Table of contents

1. The 30-second answer
2. The eight differences, ranked by patient impact
3. Difference 1: FDA indication and approval pathway
4. Difference 2: National Drug Codes and pharmacy claims
5. Difference 3: Patient eligibility criteria
6. Difference 4: Prescribing information and dose-targeting
7. Difference 5: Insurance category and coverage
8. Difference 6: Savings card programs
9. Difference 7: Direct-to-consumer vial availability
10. Difference 8: Carton, color, and packaging
11. What is exactly the same
12. Why a single drug ended up with two brands
13. Compounded tirzepatide as a third option
14. FAQ

The eight differences, ranked by patient impact

Rank	Difference	Why it matters
1	Insurance coverage	Mounjaro widely covered for diabetes; Zepbound coverage is patchy
2	FDA indication	Determines who can be prescribed which brand
3	Savings programs	Different cards, different discount structures
4	Patient eligibility	BMI thresholds for Zepbound; A1c-driven for Mounjaro
5	LillyDirect cash-pay vials	Available for Zepbound, not Mounjaro
6	Dose-targeting strategy	Glycemic control vs. weight-loss goal
7	NDC codes	Affects pharmacy claim processing and prior auth
8	Pen color and carton	Cosmetic only

For a patient choosing between the two, the top 3 differences are likely to be the deciding ones. The bottom 5 are mostly behind-the-scenes administrative differences that show up in claim processing, not in how the drug works.

Difference 1: FDA indication and approval pathway

This is the foundation that creates all the others.

Mounjaro:

• FDA approval date: May 13, 2022.
• Indication: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
• Registration trials: SURPASS-1 through SURPASS-5 (Frias et al., NEJM 2021; Rosenstock et al., Lancet 2021; Ludvik et al., Lancet 2021).
• Primary endpoint in registration trials: Reduction in hemoglobin A1c.

Zepbound:

• FDA approval date: November 8, 2023.
• Indication: Adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbid condition such as type 2 diabetes, hypertension, or dyslipidemia.
• Secondary indication added 2024: Moderate to severe obstructive sleep apnea in adults with obesity.
• Registration trial: SURMOUNT-1 (Jastreboff et al., NEJM 2022). Subsequent SURMOUNT trials continue to expand the evidence base.
• Primary endpoint in registration trial: Percent change in body weight at 72 weeks.

The two indication pathways are governed by different FDA review divisions and different statutory categories. Once a drug is approved for an indication, that indication shapes everything downstream: who can be prescribed it, how insurance categorizes it, and what the manufacturer can market.

Difference 2: National Drug Codes and pharmacy claims

Each prescription drug has a unique 11-digit National Drug Code (NDC) for each combination of formulation, dose strength, and package size.

Mounjaro and Zepbound have separate NDCs for each dose strength (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg). A pharmacy's claim system processes each as a distinct product.

The practical effects:

• Substitution is not allowed. A pharmacy cannot fill a Mounjaro prescription with Zepbound, even though the active drug is the same. The prescription must match the brand, and the prescribed brand must match the dispensed brand.
• Insurance prior authorizations are brand-specific. A patient who has PA approval for Mounjaro must obtain a new PA if they switch to Zepbound.
• Drug shortage tracking is brand-specific. The FDA's drug shortage database lists Mounjaro and Zepbound separately. One brand can be on the shortage list while the other is not, even though the underlying API is the same.

If a brand is in shortage and the prescriber switches to the other brand, the pharmacy needs a new prescription with the new NDC.

Difference 3: Patient eligibility criteria

The criteria for who can be prescribed each brand are tied to the FDA indication.

Mounjaro eligibility (per FDA label):

• Adults with type 2 diabetes mellitus.
• Used as an adjunct to diet and exercise.
• Not indicated for type 1 diabetes.
• Contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Zepbound eligibility (per FDA label):

• Adults with obesity (BMI 30 or higher) OR
• Adults with overweight (BMI 27 or higher) AND at least one weight-related comorbid condition (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease).
• Used as an adjunct to a reduced-calorie diet and increased physical activity.
• Same medullary thyroid carcinoma contraindication.

Many patients qualify for either or both. A patient with type 2 diabetes and BMI 35 is eligible for either brand. A patient with type 2 diabetes and BMI 26 is eligible only for Mounjaro. A patient with BMI 32 and no diabetes is eligible only for Zepbound.

The choice is usually driven by insurance coverage, savings card eligibility, and the prescriber's clinical judgment about the primary treatment goal.

Difference 4: Prescribing information and dose-targeting

The prescribing information documents differ in their dose-titration recommendations and target dose strategies, even though the same dose strengths are available.

Mounjaro prescribing information dose strategy:

• Start at 2.5 mg weekly for 4 weeks (initiation, not therapeutic).
• Increase to 5 mg weekly. Most patients reach effective glycemic control at 5 to 10 mg.
• Further titration to 12.5 or 15 mg if A1c targets are not met.
• Maximum dose: 15 mg.

Zepbound prescribing information dose strategy:

• Start at 2.5 mg weekly for 4 weeks (initiation).
• Increase to 5 mg weekly for at least 4 weeks.
• Continue stepwise titration up to maintenance dose, with maintenance options of 5, 10, or 15 mg weekly.
• Maximum dose: 15 mg.

For diabetes, the lowest effective dose for glycemic control is the goal. Many Mounjaro patients stay at 5 mg or 10 mg if A1c is in target.

For weight management, higher doses generally produce more weight loss within tolerance, so many Zepbound patients titrate to 10 mg, 12.5 mg, or 15 mg to maximize the weight-loss effect.

The dose strengths and the underlying drug are the same. The clinical decisions about which dose to settle at differ based on the treatment goal.

Difference 5: Insurance category and coverage

This is the difference patients feel most.

Mounjaro insurance reality:

• Most commercial insurance plans cover Mounjaro for type 2 diabetes, often with prior authorization.
• Medicare Part D covers Mounjaro on a specialty tier.
• Most state Medicaid programs cover Mounjaro for diabetes, with PA.
• The PA approval rate for Mounjaro on diabetes indication is high.

Zepbound insurance reality:

• Commercial coverage varies dramatically. Some employer plans cover Zepbound; many exclude weight-loss medications entirely.
• Medicare Part D generally does not cover Zepbound for weight loss because of the long-standing statutory exclusion of weight-loss drugs.
• Some Medicare plans cover Zepbound under the 2024 sleep apnea indication.
• State Medicaid coverage is patchy. As of Q1 2026, fewer than half of states cover Zepbound for weight management.
• Coverage is expanding gradually but the gap with Mounjaro remains large.

A 2024 analysis (Berry et al., JAMA Health Forum 2024) reported that 34% of new tirzepatide weight-management prescriptions required PA, with a denial rate around 28% on first submission. Diabetes prescriptions had higher first-pass approval rates.

For patients without strong insurance, the coverage gap drives the choice of brand more than any clinical consideration.

Difference 6: Savings card programs

Eli Lilly runs separate savings card programs for each brand, with different eligibility rules and benefit structures.

Mounjaro Savings Card:

• Available to commercially insured patients with type 2 diabetes coverage.
• Reduces copay to as little as $25 per month.
• Maximum benefit per fill is plan-specific, generally up to $573.
• Excludes Medicare, Medicaid, TRICARE, VA, and other government-funded coverage.
• 13 fills per year.

Zepbound Savings Card:

• Available to commercially insured patients regardless of whether the plan covers Zepbound.
• Two tiers:
• With insurance coverage for Zepbound: copay reduced to as little as $25 per month.
• Without insurance coverage for Zepbound: discount of approximately $463 per fill, bringing cash price to roughly $549 per month.
• Same government-program exclusions.
• 13 fills per year.

The Zepbound card's "no coverage" tier is unusual in pharma. It exists because so many commercial plans exclude Zepbound, and Lilly built a backup discount path into the program. The Mounjaro card does not have an equivalent tier because Mounjaro is more uniformly covered.

A patient cannot use both cards. The card must match the brand on the prescription.

Difference 7: Direct-to-consumer vial availability

In late 2024, Eli Lilly launched LillyDirect, a direct-to-consumer service that sells Zepbound in single-dose vials for cash-paying patients. The vials are an alternative to the prefilled pens.

LillyDirect Zepbound vials (Q1 2026):

• 2.5 mg: $349/month
• 5 mg: $549/month
• 7.5 mg: $599/month
• 10 mg: $699/month

The vials are filled with the same FDA-approved Zepbound product, but in a multi-dose vial format that requires the patient to draw the dose with an insulin syringe. The cash-pay model bypasses insurance entirely.

There is no equivalent program for Mounjaro. LillyDirect Mounjaro vials are not currently sold. Mounjaro patients who want a cash-pay option without going through insurance must use the Mounjaro Savings Card with a commercial insurance card or pay full retail.

Difference 8: Carton, color, and packaging

The carton designs and pen exterior colors differ between the two brands. Mounjaro pens use one set of brand colors; Zepbound pens use another.

The internal mechanism of the pen, the cartridge, the needle, and the dose-delivery system are identical. The pens are functionally the same device with different exterior branding.

This is the only purely cosmetic difference on the list. It exists because the two brands need to be visually distinct at the pharmacy and at the patient level to avoid confusion. The functional implications are zero.

What is exactly the same

It is worth being explicit about what is not different, because the list is long.

• The active pharmaceutical ingredient: tirzepatide.
• The molecular structure: a 39-amino-acid peptide modified with a fatty acid chain, identical between the two brands.
• The manufacturing process and source of the API.
• The dose strengths offered: 2.5, 5, 7.5, 10, 12.5, 15 mg.
• The pen mechanism and injection technique.
• The once-weekly subcutaneous injection schedule.
• The titration protocol from 2.5 mg starter dose.
• The pharmacokinetics: half-life of about 5 days, steady state in 4 weeks.
• The mechanism of action: dual GIP and GLP-1 receptor agonism.
• The side-effect profile.
• The black-box warning for medullary thyroid carcinoma.
• The contraindications.
• The storage requirements: 36°F to 46°F refrigerated, up to 21 days at room temperature, never freeze.
• The drug interactions.
• The renal and hepatic dose adjustments (none required for either).

If a patient knows what to expect from one brand at a given dose, they know what to expect from the other at the same dose.

Why a single drug ended up with two brands

The question many patients ask: if it is the same drug, why are there two brand names?

The answer is structural to U.S. pharmaceutical commercialization.

1. Indication-specific FDA approval. The FDA does not automatically extend an approval from one indication to another. Lilly had to file separate applications, run separate trial programs, and seek separate approvals for diabetes (Mounjaro) and weight management (Zepbound). Each approval is independently maintained.

2. Insurance benefit categories. Insurance plans treat diabetes drugs and anti-obesity drugs as different benefit categories with different formulary rules, prior authorization protocols, and payer pricing. A single brand serving both indications would have to be categorized as one or the other in each plan's formulary, which would make it harder to negotiate optimal coverage.

3. Differentiated copay assistance and pricing. Manufacturers can run different savings card programs and direct-to-consumer initiatives for each brand. The Zepbound program has a cash-pay tier; the Mounjaro program does not.

4. Patient and prescriber clarity. A diabetes patient and a weight-loss patient see different clinical contexts. Two brand names reduce confusion at the pharmacy counter and in clinical communication.

The pattern is consistent in pharma. Semaglutide is sold as Ozempic for diabetes and Wegovy for weight management. Liraglutide was sold as Victoza for diabetes and Saxenda for weight management. Bupropion is sold as Wellbutrin for depression and Zyban for smoking cessation. Topiramate is sold as Topamax for epilepsy and is part of Qsymia for weight management. Same drug, multiple brands, different indications.

Compounded tirzepatide as a third option

Outside of Mounjaro and Zepbound, U.S. patients can access tirzepatide through state-licensed compounding pharmacies. Compounded tirzepatide is prepared under individual prescriptions and dispensed as a multi-dose vial.

Pricing typically runs $199 to $399 per month, often without insurance.

Trade-offs versus brand-name:

• Not FDA-approved.
• Vial-and-syringe instead of prefilled pen.
• Concentration varies between pharmacies, so the same dose in milligrams can require different unit counts on the syringe.
• Reputable compounders work only with patients who have a current prescription from a licensed clinician.
• The molecule is the same tirzepatide.

For patients without insurance coverage for either brand, compounded is often the cheapest legitimate path. For patients with insurance coverage and savings card eligibility on a brand, the brand-name path is usually cheaper.

FAQ

What is the main difference between Mounjaro and Zepbound? The main difference is the FDA-approved indication. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management. Both contain the same drug, tirzepatide, at the same doses, in the same pen format. The molecule, clinical effect, and side-effect profile are identical.

Is the active ingredient in Mounjaro and Zepbound the same? Yes. Both products contain tirzepatide as the active ingredient. The molecule, manufacturer, and dose strengths are identical between the brands.

Why do Mounjaro and Zepbound exist separately? The two brands let Eli Lilly serve two FDA-approved indications (type 2 diabetes and chronic weight management) with distinct insurance pathways, savings programs, and prescribing rules. The pattern is common in pharma when one drug treats multiple conditions covered under different insurance benefit categories.

Can I take Mounjaro for weight loss? Mounjaro is FDA-approved for type 2 diabetes only. Some prescribers write it off-label for weight loss, but most insurance plans do not cover off-label use. The on-label option for weight management is Zepbound.

Can I take Zepbound for diabetes? Zepbound is FDA-approved for chronic weight management. Some prescribers may use it off-label for diabetes, but the on-label option for diabetes is Mounjaro. Insurance coverage for off-label use is rare.

Is Mounjaro more effective than Zepbound, or vice versa? No. The drug is identical, so the effect on body weight, blood sugar, and other metabolic markers is the same at the same dose. The dose-targeting strategies differ between diabetes and weight-management contexts, which can produce different outcomes for the same patient depending on what is being optimized.

Are the side effects the same? Yes. The side effects are identical because the drug is identical. Patients tolerate one brand the same way they tolerate the other at the same dose.

Is one brand cheaper than the other? Wholesale list prices are nearly the same (around $1,060 to $1,070 per month). Out-of-pocket cost varies based on insurance coverage and savings card eligibility. Mounjaro tends to be cheaper for insured diabetes patients. Zepbound has a cash-pay savings card option that Mounjaro does not.

Can my pharmacist swap Mounjaro for Zepbound or vice versa? No. Each brand has separate NDC codes and FDA indications. The prescription must match the brand, and the dispensed product must match the prescription. Switching requires a new prescription from the prescriber.

What if my insurance covers Mounjaro but not Zepbound, and I need it for weight loss? The standard path is to ask your prescriber whether off-label Mounjaro is appropriate for your situation. Coverage for off-label use is rare, so most patients in this situation either appeal Zepbound coverage with their insurance, switch to compounded tirzepatide, or use the LillyDirect Zepbound cash-pay vial program.

Do Mounjaro and Zepbound have the same FDA black-box warning? Yes. Both carry the same boxed warning about thyroid C-cell tumors, including medullary thyroid carcinoma. Patients with personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 should not take either.

Will the difference between Mounjaro and Zepbound matter when generic tirzepatide arrives? When generic tirzepatide is approved in the future (the earliest patent expirations are in the early 2030s), generics will likely be approved by indication, similar to brand-name. Generics for the diabetes indication and the weight-management indication may launch separately or together. The brand-name distinction will fade in significance as generics enter both categories.

Sources

1. Eli Lilly. Mounjaro (tirzepatide) prescribing information. Revised 2024.
2. Eli Lilly. Zepbound (tirzepatide) prescribing information. Revised 2024.
3. Frias JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515.
4. Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021;398(10295):143-155.
5. Ludvik B, et al. Tirzepatide versus insulin degludec in type 2 diabetes (SURPASS-3). Lancet. 2021;398(10300):583-598.
6. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
7. Berry SD, et al. Prior authorization patterns for GLP-1 receptor agonists in U.S. commercial insurance, 2023-2024. JAMA Health Forum. 2024;5(8):e242117.
8. U.S. Food and Drug Administration. Mounjaro and Zepbound approval letters and prescribing information, May 2022 and November 2023.
9. Malhotra A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med. 2024;391(13):1193-1205.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly.